Over the past 12 months, 5 insiders at AN2 Therapeutics, Inc. filed 13 open-market SEC Form 4 transactions on ANTX: 0 purchases worth $0 and 13 sales worth $80K. Insiders have been net sellers over this period. The most recent filing was on Jul 8, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 8, 26 | Joshua M EizenSee Remarks | SELL | 5.9K | $4.17 | $25K |
| May 29, 26 | Sarah Joanne WilliamsPrincipal Accounting Officer | SELL | 265 | $4.43 | $1K |
| Mar 3, 26 | Sarah Joanne WilliamsPrincipal Accounting Officer | SELL | 327 | $1.06 | $347 |
| Jan 6, 26 | Sanjay ChandaChief Development Officer | SELL | 6.0K | $1.01 | $6K |
| Jan 6, 26 | Lucy DayChief Financial Officer | SELL | 5.5K | $1.01 | $6K |
| Jan 6, 26 | Joshua M EizenSee Remarks | SELL | 6.9K | $1.01 | $7K |
| Jan 6, 26 | Stephen David PriorChief Strategy Officer | SELL | 2.9K | $1.01 | $3K |
| Jan 5, 26 | Sanjay ChandaChief Development Officer | SELL | 3.3K | $1.00 | $3K |
| Jan 5, 26 | Lucy DayChief Financial Officer | SELL | 3.3K | $1.00 | $3K |
| Jan 5, 26 | Joshua M EizenSee Remarks | SELL | 17.9K | $1.00 | $18K |
| Jan 5, 26 | Stephen David PriorChief Strategy Officer | SELL | 3.6K | $1.00 | $4K |
| Nov 4, 25 | Joshua M EizenSee Remarks | SELL | 2.8K | $1.14 | $3K |
| Nov 4, 25 | Stephen David PriorChief Strategy Officer | SELL | 765 | $1.14 | $872 |
| Jun 2, 25 | Eric EasomChief Executive Officer | BUY | 10.0K | $1.07 | $11K |
| May 30, 25 | Braden Michael LeonardTenPercentOwner | SELL | 425.0K | $1.03 | $429K |
| May 28, 25 | Margaret M FitzpatrickDirector | BUY | 8.6K | $1.18 | $10K |
| May 28, 25 | Braden Michael LeonardTenPercentOwner | SELL | 2.00M | $1.16 | $2.3M |
| Jan 3, 25 | Sanjay ChandaChief Development Officer | SELL | 3.0K | $1.34 | $4K |
| Jan 3, 25 | Lucy DayChief Financial Officer | SELL | 3.0K | $1.34 | $4K |
| Jan 3, 25 | Joshua M EizenSee Remarks | SELL | 9.7K | $1.34 | $13K |
| Jan 3, 25 | Stephen David PriorChief Strategy Officer | SELL | 2.0K | $1.34 | $3K |
| Dec 10, 24 | Robin Shane ReadnourDirector | BUY | 5.0K | $1.49 | $7K |
| Dec 9, 24 | Robin Shane ReadnourDirector | BUY | 18.5K | $1.43 | $26K |
| Dec 6, 24 | Robin Shane ReadnourDirector | BUY | 12.7K | $1.45 | $18K |
| Nov 27, 24 | Joseph S ZakrzewskiDirector | BUY | 2.0K | $1.40 | $3K |
| Nov 27, 24 | Robin Shane ReadnourDirector | BUY | 25.0K | $1.42 | $36K |
| Nov 26, 24 | Robin Shane ReadnourDirector | BUY | 12.5K | $1.39 | $17K |
| Nov 20, 24 | Robin Shane ReadnourDirector | BUY | 25.0K | $1.15 | $29K |
| Nov 19, 24 | Robin Shane ReadnourDirector | BUY | 75.0K | $1.04 | $78K |
| Nov 19, 24 | Joseph S ZakrzewskiDirector | BUY | 5.0K | $1.01 | $5K |
| Nov 18, 24 | Eric EasomChief Executive Officer | BUY | 50.0K | $1.00 | $50K |
| Nov 18, 24 | Joseph S ZakrzewskiDirector | BUY | 20.0K | $1.00 | $20K |
| Aug 14, 24 | Braden Michael LeonardTenPercentOwner | BUY | 1.50M | $1.04 | $1.6M |
| Aug 9, 24 | Ra Capital Healthcare Fund LpTenPercentOwner | SELL | 3.41M | $1.08 | $3.7M |
| Jan 18, 24 | Joseph S ZakrzewskiDirector | SELL | 100.0K | $19.11 | $1.9M |
| Jan 16, 24 | Adjuvant Capital Management, LlcTenPercentOwner | SELL | 84.1K | $19.65 | $1.7M |
| Jan 16, 24 | Kabeer AzizDirector | SELL | 84.1K | $19.65 | $1.7M |
| Jan 12, 24 | Robin Shane ReadnourDirector | SELL | 719 | $21.92 | $16K |
| Jan 10, 24 | Robin Shane ReadnourDirector | SELL | 1.9K | $21.93 | $41K |
| Jan 9, 24 | Kevin Michael KrauseChief Strategy Officer | SELL | 7.4K | $20.14 | $149K |
| Jan 2, 24 | Eric EasomChief Executive Officer | SELL | 2.8K | $20.09 | $56K |
| Jan 2, 24 | Kevin Michael KrauseChief Strategy Officer | SELL | 2.6K | $20.12 | $52K |
| Nov 14, 23 | Adjuvant Capital Management, LlcTenPercentOwner | SELL | 1.5K | $16.15 | $25K |
| Nov 14, 23 | Kabeer AzizDirector,TenPercentOwner | SELL | 1.5K | $16.15 | $25K |
| Oct 2, 23 | Adjuvant Global Health Technology Fund, L.p.TenPercentOwner | SELL | 4.8K | $16.07 | $77K |
| Oct 2, 23 | Kabeer AzizDirector,TenPercentOwner | SELL | 4.8K | $16.07 | $77K |
| Sep 29, 23 | Adjuvant Global Health Technology Fund, L.p.TenPercentOwner | SELL | 83.3K | $16.28 | $1.4M |
| Sep 29, 23 | Kabeer AzizDirector,TenPercentOwner | SELL | 83.3K | $16.28 | $1.4M |
| Sep 28, 23 | Adjuvant Global Health Technology Fund De, L.p.TenPercentOwner | SELL | 7.2K | $16.11 | $115K |
| Sep 28, 23 | Kabeer AzizDirector,TenPercentOwner | SELL | 7.2K | $16.11 | $115K |
Over the past 12 months, insiders at AN2 Therapeutics, Inc. filed 0 open-market purchases worth $0 and 13 sales worth $80K on ANTX, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 8, 26.
The largest recent open-market ANTX insider purchase in our data was $1.6M by Braden Michael Leonard, TenPercentOwner, filed on Aug 14, 24.
5 different insiders at AN2 Therapeutics, Inc. filed open-market SEC Form 4 transactions on ANTX over the last 12 months.
InsiderTape plots every ANTX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every AN2 Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →